Human CD331/FGFR1 (OM-RCA-01) Antibody is a research-grade biosimilar monoclonal antibody. It is a human IgG1-kappa antibody. Reactivity: Human. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, flow cytometry, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% purity as determined by SDS-PAGE. For research use only.
Fibroblast growth factor receptor 1 (CD331/FGFR1) is a ~91 kDa protein. Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of embryonic development, cell proliferation, differentiation and migration. Required for normal mesoderm patterning and correct axial organization during embryonic development, normal skeletogenesis and normal development of the gonadotropin-releasing hormone (GnRH) neuronal system. Phosphorylates PLCG1, FRS2, GAB1 and SHB. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate.
Product Name:
Human CD331/FGFR1 (OM-RCA-01) Antibody
SKU:
GXBS01302
Size:
100 µg, 1 mg
Antibody Type:
Monoclonal Antibody
Clone:
OM-RCA-01
Target:
FLT2
Isotype:
IgG1-kappa
Host Species:
Human
Reactivity:
Human
Applications:
ELISA, FCM, Functional assay, Research in vivo
Expression Host:
Mammalian cells
Synonyms:
OM-RCA-01
Biological Activity:
OM-RCA-01 binds to FGFR1 with high affinity (K d = 1.59 nM) and inhibits its in vitro kinase activity [1]. OM-RCA-01 (1-100 ug/mL, 3 h) potently inhibits FGFR1 phosphorylation and cell proliferation in FGFR1-overexpressing human lung cancer cell line A549 (GI 50 = 9.69 ug/mL), but exerts no significant effect on FGFR1-low-expressing human melanoma cell line Mel Kor [1]. OM-RCA-01 (0.5-10 nmol/L; 5 days) enhances Nivolumab -induced IFN-γ release and T-cell proliferation in a human allogeneic MLR assay, whereas it exhibits minimal effects when used alone when combined with Nivolumab () [1]. OM-RCA-01 (1 ug/mL; 4 days) increases Nivolumab -induced IL-2 secretion by 29%-74% in human peripheral blood mononuclear cells (PBMCs) stimulated with Staphylococcal enterotoxin B (SEB) () [1]. Western Blot Analysis [1] Cell Line: A549 cells Concentration: 1-100ug/mL Incubation Time: 3 h Result: Resulted in a dose-dependent suppression of FGFR1 phosphorylation. Parmacokinetics Species Dose Route C 0 T 1/2 V d CL AUC 0-t AUC 0-∞ MRT Rat [1] 10 mg/kg i.v. 186 ng/mL 121 h 532 L 3.05 L/h 10665 ng·h/mL 32818 ng·h/mL 34 h Rat [1] 30 mg/kg i.v. 177 ng/mL 136 h 2533 L 12.88 L/h 14237 ng·h/mL 46602 ng·h/mL 34 h Rat [1] 100 mg/kg i.v. 245 ng/mL 234 h 7569 L 22.44 L/h 16383 ng·h/mL 89131 ng·h/mL 35 h OM-RCA-01 (30 mg/kg; i.v.; twice weekly) induces a statistically significant two-fold reduction in median tumor volume and delays tumor growth in A549 lung cancer xenograft models, and combination with Pembrolizumab () achieves 89% tumor growth inhibition [1]. OM-RCA-01 (30 mg/kg; once every 3 days) achieves 96% tumor growth delay in the cancer-associated fibroblast (CAF)-positive renal cell carcinoma cohort and 75% tumor growth delay in the CAF-negative renal cell carcinoma cohort, while increasing IFN-γ and IL-2 cytokine levels [1].
Purity:
>95% as determined by SDS-PAGE.
Endotoxin Level:
< 10 EU/mg
Formulation:
0.01M PBS pH 7.4.
State of Matter:
Liquid
Regulatory Status:
For research use only. Not suitable for clinical or therapeutic use.
Product Preparation:
Protein A/G purified from cell culture supernatant.
Storage and Handling:
Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
